Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The University of Texas MD Anderson Cancer Center and Theraclone Sciences have launched a company called OncoResponse that will use Theraclone’s screening technology to identify therapeutic antibodies against novel targets from immuno-oncology-treated patients. MD Anderson will provide access to samples and data from patients who have responded well to cancer immunotherapies. OncoResponse has raised $9.5 million in financing from Arch Venture Partners, Canaan Partners, MD Anderson, and others.
This article has been sent to the following recipient: